A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: Studies in knock-out mice

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1500, Issue 3, 2000, Pages 280-290

  Zhao, Zhihui ^a   Makaritsis, Konstantinos ^a   Francis, Cynthia E ^a   Gavras, Haralambos ^a   Ravid, Katya ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE A3 RECEPTOR; CYCLIC AMP;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CELL LEVEL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; FEMALE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STRAIN DIFFERENCE; TISSUE DISTRIBUTION;

ADENOSINE; ANIMALS; AORTA; BLOOD PLATELETS; BLOOD PRESSURE; CYCLIC AMP; IN SITU HYBRIDIZATION; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; PLATELET ACTIVATION; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1;

ANIMALIA;

EID: 0034006346     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(99)00111-8     Document Type: Article

References (53)

1. Mubagwa K., Mullane K., Flameng W. Role of adenosine in the heart and circulation. Cardiovasc. Res. 32:1996;797-813.
2. Olah M.E., Stiles G.L. Adenosine receptor subtypes characterization and therapeutic regulation. Ann. Rev. Physiol. 54:1992;211-225.
3. Tucker A.L., Linden J. Cloned receptors and cardiovascular responses to adenosine. Cardiovasc. Res. 27:1993;62-67.
4. Linden J. Cloned adenosine A3 receptors:pharmacological properties, species differences and receptor functions. Trends Pharmacol. Sci. 15:1994;298-306.
5. Salvatore C.A., Jacobson M.A., Taylor H.E., Linden J., Johnson R.G. Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Natl. Acad. Sci. USA. 90:1993;10365-10369.
6. Williams M. Purine receptors in mammalian tissues pharmacology and functional significance. Annu. Rev. Pharmacol. Toxicol. 27:1987;315-345.
7. Van Calker D., Muller M., Hamprecht B. Adenosine regulates via two different receptors the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33:1979;999-1005.
8. Kitakaze M., Hori M., Kamada T. Role of adenosine and its interaction with alpha adrenoceptor activity in ischaemic and reperfusion injury of the myocardium. Cardiovasc. Res. 27:(1):1993;18-27.
9. Belardinelli L., Linden J., Berne R.M. The cardiac effects of adenosine. Progr. Cardiovasc. Dis. 32:1989;73-97.
10. Ely S.W., Berne R.M. Protective effects of adenosine in myocardial ischemia. Circulation. 85:1992;893-904.
11. Downey J.M. Ischemic preconditioning: nature's own cardioprotective intervention. Trends Cardiovasc. Med. 2:1992;170-176.
12. Rossi N., Churchill P., Ellis V., Amore B. Mechanism of adenosine receptor-induced renal vasoconstriction in rats. Am. J. Physiol. 255:(4):1988;H885-H890.
13. P.C. Churchill, A. Bidani, in: M. Williams (Ed.), Adenosine and adenosine receptor, Humana, Clifton, NJ, 1990.
14. Hutchison A.J., Webb R.L., Oei H.H., Ghai G.R., Simmerman M.B., Williams M. CGS 21680C, and A2 selective adenosine receptor agonist with preferential hypotensive activity. J. Pharmacol. Exp. Ther. 251:(1):1989;47-55.
15. K.M. Mullane, M. Williams, Adenosine and cardiovascular function, in: M. Williams (Ed.), Adenosine and Adenosine Receptors, The Humana Press, Clifton, NJ, 1990, pp. 289-333.
16. Zhao Z., Francis C.E., Ravid K. An A3-subtype adenosine receptor is highly expressed in rat vascular smooth muscle cells its role in attenuatng adenosine-induced increase in cAMP. Microvasc. Res. 54:1997;243-252.
17. Zhou Q.Y., Li C., Olah M.E., Johnson R.A., Stiles G.L., Civelli O. Molecular cloning and characterization of an adenosine receptor the A3 adenosine receptor. Proc. Natl. Acad. Sci. USA. 89:1992;7432-7436.
18. C.A. Salvatore, S.L. Tilley, D.S. Fletcher, A.M. Latour, B.H. Kollen, M.A. Jacobson, Targeted disruption of the A3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells, J. Biol. Chem., submitted for publication.
19. Ravid K., Beeler D.L., Rabin M.S., Ruley E., Rosenberg R.D. Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter (in transgenic mice). Proc. Natl. Acad. Sci. USA. 88:1991;1521-1525.
20. Hechler B., Eckly A., Ohlmann P., Cazenave J.P., Gachet C. The P2Y receptor is necessary but not sufficient to support full ADP-induced platelets aggregation: evidence for the presence of another P2Y receptor. Br. J. Haematol. 103:1998;858-866.
21. Makaritsis K.P., Handy D.E., Johns C., Kobilka B., Gavras L., Gavras H. Role of the a2B-adrenergic receptor in salt-induced hypertension. Hypertension. 33:1999;14-17.
22. Johns C., Gavras I., Handy D.E., Salomao A., Gavras H. Models of experimental hypertension in mice. Hypertension. 28:1996;1064-1069.
23. Toselli P., Faris B., Sassoon D., Jackson B.A., Franzblau C. In-situ hybridization of tropoelastin mRNA during the development of the multilayered neonatal rat aortic smooth muscle cell culture. Matrix. 12:1992;321-332.
24. Zimmet J., Ladd D., Jackson C.W., Stenberg P.E., Ravid K. A role for cyclin D3 in the endomitotic cell cycle. Mol. Cell. Biol. 17:1997;7248-7259.
25. Zhao Z., Francis C., Ravid K. Characterization of the mouse A3 adenosine receptor gene exon/intron organization and promoter activity. Genomics. 57:1999;152-155.
26. Gallo-Rodriguezetal C., et al. Structure-activity relationships of N6-benzyladenosine-5′-uronamides as A3-selective adenosine agonists. J. Med. Chem. 37:1994;636-646.
27. Lerman B.B., Belardinelli L. Cardiac electrophysiology of adenosine: basic and clinical concepts. Circulation. 83:1991;1499-1509.
28. Frick G.P., Lowenstien J.M. Studies of '5'-nucleotidase in the perfused rat heart. J. Biol. Chem. 251:1976;6372-6378.
29. Itoh R., Oka J., Ozawa H. Regulation of rat heart cytosol 5′-nucleotidase by adenylate energy charge. Biochem. J. 235:1986;847-851.
30. Schrader J., Thompson C.I., Hiendlmayer G., Gerlach E. Role of purines in acetylcholine-induced coronary vasodilatation. J. Mol. Cell. Cardiol. 14:1982;427-430.
31. K.M. Mullane, in: E. Sonnenblick, J.H. Laragh, M. Lesch (Eds.), Current Perspectives of ACE Inhibitors: From Mechanism to Therapy, Excerpta Medica, Boston, MA, 1989, pp. 234-270.
32. Olafsson B., Farman M.B., Puett D.W., Pou A., Cates C.U., Friesinger G.C., Virman R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation. 76:1987;1135-1145.
33. Webb R.L., McNeal R.B.J., Barclay B.W., Yasay G.D. Hemodynamic effects of adenosine agonists in the conscious spontaneously hypertensive rat. J. Pharmacol. Exp. Ther. 254:1990;1090-1099.
34. Klotz K.N., Hessling J., Hegler J., Owman C., Kull B., Fredholm B.B., Lohse M.J. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1998;1-9.
35. Shepherd R.K., Linden J., Duling B.R. Adenosine-induced vasoconstriction in vivo: role of mast and A3 adenosine receptor. Circ. Res. 78:1996;627-634.
36. Belardinelli L., Isenberg G. Isolated atrial myocytes: adenosine and acetylcholine increase potassium conductance. Am. J. Physiol. 244:1983;H734-H737.
37. Kurachi Y., Nakajima T., Sugimoto T. On the mechanism of activation of muscarinic K+ channels by adenosine in isolated atrial cells: involvement of GTP-binding proteins. Pflugers Arch. Eur. J. Physiol. 407:1986;264-274.
38. L. Belardinelli, S.N. Wu, S. Visentin, in: D.P. Zipes, J. Jalife (Eds.), Cardiac Electrophysiology: From Cell to Bedside, W.B. Saunders, Philadelphia, PA, 1990, pp. 344-353.
39. Lamonica D.A., Frohloff N., Dobson J.G. Adenosine inhibition of catecholamine-stimulated cardiac membrane adenylyl cyclase. Am. J. Physiol. 248:1985;H737-H744.
40. Liang B.T. Characterization of the adenosine receptor in cultured embryonic chick atrial myocytes: coupling to modulation of contractility and adenylyl cyclase activity and identification of direct radioligand binding. J. Pharmacol. Exp. Ther. 249:1989;755-784.
41. Haslem R.J., Daridson M.M., Desjardins J.V. Inhibition of adenylyl cyclase by adenosine analogs in preparations of broken and intact human platelets. Biochem. J. 176:1987;83-95.
42. Ferrer V.Q., Hultgardh-Nilsson A., Ringertz N.R., Nilson J., Jonzon B. Adenosine receptors, cAMP accumulation, DNA synthesis in aortic smooth muscle cell cultures of adult and neonaral rats. J. Cell. Physiol. 151:1992;555-560.
43. Wolff J., Londo S.C., Cooper D.M.F. Adenosine receptors and the regulation of adenylyl cyclase. Adv. Cycl. Nucleot. Res. 14:1981;199-214.
44. Ribeiro J.A., Sebastiao A.M. Adenosine receptors and calcium basis for proposing a third (A3) adenosine receptor. Progr. Neurobiol. 26:1986;179-209.
45. G. Isenberg, E. Cerbai, U. Klockner, in: E. Gerlach, B.F. Becker (Eds.), Topics and Perspectives in Adenosine Research, Springer-Verlag, Berlin, 1987, pp. 323-335.
46. Gerwin P., Fredholm B.B. ATP and its metabolite adenosine act synergistically to mobilize intracellular calcium via the formation of inositol 1,4,5-trisphosphate in a smooth muscle cell line. J. Biol. Chem. 267:1992;16081-16087.
47. Hill G.E., Anderson J.L., Lyden E.R. Ketamine inhibits the proinflammatory cytokine-induced reduction of cardiac intracellular cAMP accumulation. Anesth. Analg. 87:1998;1015-1019.
48. Marcil J., de Champlain J., Anand-Srivastava M.B. Overexpression of Gi-proteins precedes the development of DOCA-salt-induced hypertension relationship with adenylyl cyclase. Cardiovasc. Res. 39:1998;492-505.
49. Hegedus K., Keresztes T., Fekete I., Molnar L. Effect of i.v. dipyridamole on cerebral blood flow, blood pressue, plasma adenosine and cAMP levels in rabbits. J. Neurol. Sci. 148:1997;153-161.
50. Farrell D.M., Bishop V.S. The roles of cGMP and cAMP in active thermoregulatory vasodilation. Am. J. Physiol. 272:1997;R975-R981.
51. Armstead W.M. Role of nitric oxide, cyclic nucleotides, and the activation of ATP-sensitive K+ channels in the contribution of adenosine to hypoxia-induced pial artery dilation. J. Cereb. Blood Flow Metab. 17:1997;100-108.
52. Bell D.R., Dec E.M., Rensberger H.J. Selective effect of high arterial pressure in hypertension upon inhibition of cGMP versus cAMP mediated vascular relaxation. Clin. Exp. Hypertens. 18:1996;773-791.
53. Anand-Srivastava M.B. G-proteins and adenylyl cyclase signalling in hypertension. Mol. Cell. Biochem. 157:1996;163-170.